↓ Skip to main content

Engagement of the private pharmaceutical sector for TB control: rhetoric or reality?

Overview of attention for article published in Journal of Pharmaceutical Policy and Practice, January 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#1 of 170)
  • High Attention Score compared to outputs of the same age (98th percentile)

Mentioned by

news
11 news outlets
twitter
42 tweeters

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
48 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Engagement of the private pharmaceutical sector for TB control: rhetoric or reality?
Published in
Journal of Pharmaceutical Policy and Practice, January 2017
DOI 10.1186/s40545-016-0093-3
Pubmed ID
Authors

Niranjan Konduri, Emily Delmotte, Edmund Rutta

Abstract

Private-sector retail drug outlets are often the first point of contact for common health ailments, including tuberculosis (TB). Systematic reviews on public-private mix (PPM) interventions for TB did not perform in-depth reviews specifically on engaging retail drug outlets and related stakeholders in the pharmaceutical sector. Our objective was to better understand the extent to which the World Health Organization's (WHO) recommendation on engaging retail drug outlets has been translated into programmatic policy, strategy, and intervention in low- and middle-income countries. The study included a content analysis of global-level documents from WHO and the Stop TB Partnership in five phases. A country-level content analysis from four data sources was performed. Global-level findings were tabulated based on key messages related to engaging retail drug outlets. Country-level findings were analyzed based on four factors and tabulated. National strategic plans for TB control from 14 countries with varying TB burdens and a strong private sector were reviewed. 33 global-level documents and 77 full-text articles and Union World Lung Health conference abstracts were included for review. Based on experience of engaging retail drug outlets that has emerged since the mid-2000s, in 2011 WHO and the International Pharmaceutical Federation released a joint statement on promoting the engagement of national pharmacy associations in partnership with national TB programs. Only two of 14 countries' national strategic plans had explicit statements on the need to engage their national pharmacy professional association. The success rate of referrals from retail drug outlets who visited an approved health facility for TB screening ranged from 48% in Vietnam to 86% in Myanmar. Coverage of retail drug outlets ranged from less than 5 to 9% of the universe of retail drug outlets. For WHO's End TB Strategy to be successful, scaling up retail drug outlets to increase national coverage, at least in countries with a thriving private sector, will be instrumental in accelerating the early detection and referral of the 3 million missing TB cases. The proposed PPM pharmacy model is applicable not only for TB control but also to tackle the antimicrobial resistance crisis in these countries.

Twitter Demographics

The data shown below were collected from the profiles of 42 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
India 1 2%
Unknown 47 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 14 29%
Student > Ph. D. Student 9 19%
Student > Master 7 15%
Student > Postgraduate 5 10%
Lecturer 4 8%
Other 9 19%
Readers by discipline Count As %
Medicine and Dentistry 18 38%
Unspecified 7 15%
Nursing and Health Professions 7 15%
Pharmacology, Toxicology and Pharmaceutical Science 5 10%
Social Sciences 5 10%
Other 6 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 113. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 October 2017.
All research outputs
#133,997
of 13,317,108 outputs
Outputs from Journal of Pharmaceutical Policy and Practice
#1
of 170 outputs
Outputs of similar age
#6,299
of 345,072 outputs
Outputs of similar age from Journal of Pharmaceutical Policy and Practice
#1
of 1 outputs
Altmetric has tracked 13,317,108 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 170 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 345,072 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them